支持干燥病聚类及疾病进展的独特分子通路
该研究分析ASSESS队列351例干燥病患者的转录组数据,比较BALS、HSA和LSAHS三个聚类及BALS进展亚组的分子特征。结果显示BALS和HSA均上调I/II型干扰素刺激基因,BALS(尤其进展亚组)干扰素活性更强并富集炎症通路,而HSA则转向增殖与代谢通路。
要点
- BALS和HSA聚类均显示I/II型干扰素刺激基因上调,LSAHS则无此特征。
- BALS进展亚组富集IFNα/γ、TNFα、IL-6、补体激活及mTORC1通路。
- HSA聚类干扰素和KRAS通路活性减弱,转向MYC、mTOR和氧化磷酸化。
核心结论
- 干扰素信号是HSA和BALS聚类的共同标志,在BALS中可能驱动早期疾病进展,后期可被增殖通路替代而演变为HSA。
研究设计与样本
- 分析ASSESS队列(GSE140161;n=351)的转录组数据,按既定三聚类分组,并在BALS中定义进展亚组(需新免疫抑制剂和/或发生淋巴瘤)。
- 采用差异表达分析和基因集富集分析评估亚组特异性特征和生物学通路。
主要发现
- BALS和HSA相比LSAHS均显示稳健的I/II型干扰素刺激基因上调。
- BALS的干扰素活性和炎症信号强于HSA,尤其在BALS_Evol亚组中。
- BALS_Evol亚组富集IFNα/γ、TNFα、IL-6、补体激活和mTORC1通路。
- HSA聚类相比BALS显示干扰素和KRAS通路活性减弱,伴MYC、mTOR和氧化磷酸化激活。
临床怎么用
- 对干燥病患者可依据BALS、HSA、LSAHS聚类及BALS进展亚组的分子特征识别疾病进展风险。
- BALS进展亚组的干扰素及炎症通路富集提示这些通路可能作为干预靶点。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom burden (LSAHS). METHODS: We analyzed transcriptomic data from the ASSESS cohort (GSE140161; n = 351). Patients were classified into the three clusters previously described. Within BALS, an evolutive subgroup was defined based on need for new immunosuppressants and/or occurrence of lymphoma (BALS subgroup of patients with progressive/evolving disease [BALS_Evol]). Differential expression analysis and Gene Set Enrichment Analysis were performed to evaluate subgroup-specific signatures and biologic pathways. RESULTS: Both BALS and HSA displayed robust types I/II interferon (IFN)-stimulated gene up-regulation compared to LSAHS. BALS exhibited stronger IFN activity and inflammatory signaling than HSA, particularly in the evolutive subgroup (BALS_Evol). This subgroup showed enrichment of IFNα/γ, tumor necrosis factor α, interleukin-6, complement activation, and mechanistic target of rapamycin (mTOR) complex 1 pathways, indicating a hyperinflammatory and dysregulated immune state linked to disease progression. In contrast, compared with BALS, the HSA cluster displayed attenuated IFN and KRAS pathway activity, coupled with activation of MYC, mTOR, and oxidative phosphorylation, suggesting a molecular shift toward proliferation and metabolism that may promote systemic disease evolution. CONCLUSION: IFN signaling is a hallmark of both HSA and BALS clusters. In BALS, it may drive early disease progression, which can be replaced later by proliferative pathways leading to an HSA. These findings pave the way for new hypotheses regarding the mechanisms driving disease progression in SjD.
引用
- Silva-Saffar SE, Nguyen Y, Seror R, et al. Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression. Arthritis Rheumatol. 2026. PMID: 42272274. doi:10.1002/art.70251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。